Clinical data and state rules are separate facts. Both are shown; neither is a decision.
No dopamine or 5-HT2A blockade; effect on psilocybin unknown. Nausea, vomiting and raised heart rate are common; trospium is anticholinergic.
Treated as an antipsychotic medication under the rule (FDA-approved for schizophrenia), although it does not block dopamine receptors. Antipsychotic medications are named in rule, regardless of indication or dose. A Facilitator licensee may not provide services to a participant taking one without a referral for natural medicine services from a licensed provider, medical clearance from their medical or behavioral health provider, or a consultation and risk review with a medical or behavioral health provider. A Clinical Facilitator who does not prescribe antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider.
Colorado · checked 2026-09-30No provision names this medication or its class.
Oregon · checked 2026-09-30New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.
New Mexico · checked 2026-09-30This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.